Drug Trial Radar · NCT06594159
A Study of LY4065967 in Healthy Japanese Participants
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Oct 22, 2024
Primary completion
Mar 11, 2025
Study completion Mar 11, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.
Conditions
- Healthy
Interventions
LY4065967Drug
Administered orally
PlaceboDrug
Administered orally
RosuvastatinDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug AdministrationTime frame: Baseline to 7 Days
- Part B: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug AdministrationTime frame: Baseline to 12 Days
- Part D: PK: Maximum Concentration (Cmax) of RosuvastatinTime frame: Predose on Day 1 Through 72 Hours Post-Dose
- Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of RosuvastatinTime frame: Predose on Day 1 Through 72 Hours Post-Dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Souseikai Fukuoka Mirai Hospital
Fukuoka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.